{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:57:43Z","timestamp":1781301463211,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.disamonth.2026.102151","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:39:15Z","timestamp":1781300355000},"page":"102151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 agonist and neuroprotection in Stroke and Parkinson\u2019s disease: A systematic review"],"prefix":"10.1016","author":[{"given":"Drashti S","family":"Parekh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dastan","family":"Kudaiarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pugazhendi","family":"Inban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashita","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshi","family":"Prajjwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2026.102151_bib0001","unstructured":"Collins L., Costello R.A. Glucagon-like peptide-1 receptor agonists 2024."},{"key":"10.1016\/j.disamonth.2026.102151_bib0002","first-page":"3","article-title":"Long-acting GLP-1RAs: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"J Am Acad Physician Assist"},{"key":"10.1016\/j.disamonth.2026.102151_bib0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3897\/pharmacia.72.e155150","article-title":"Beyond glycemic control: the neuroprotective potential of tirzepatide","volume":"72","author":"Hristov","year":"2025","journal-title":"Pharmacia"},{"key":"10.1016\/j.disamonth.2026.102151_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01514","article-title":"Diabetic cardiomyopathy: current and future therapies. Beyond glycemic control","volume":"9","author":"Borghetti","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease","volume":"31","author":"Hong","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0007","doi-asserted-by":"crossref","unstructured":"Ros-Madrid I., Cano-M\u00e1rmol R.P., Ferrer-Gomez M., Ramos-Molina B. Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. 101139\/Cjpp-2025-0148 2025;103:369\u2013377. https:\/\/doi.org\/10.1139\/CJPP-2025-0148.","DOI":"10.1139\/cjpp-2025-0148"},{"key":"10.1016\/j.disamonth.2026.102151_bib0008","doi-asserted-by":"crossref","DOI":"10.12775\/QS.2026.51.68253","article-title":"Neuroprotective mechanisms of GLP 1 pathway activation in Parkinson's Disease - foundations for future disease modifying strategies","volume":"51","author":"Chmiel","year":"2026","journal-title":"Qual Sport"},{"key":"10.1016\/j.disamonth.2026.102151_bib0009","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0012","first-page":"1440","article-title":"Neurological conditions are leading cause of disability worldwide","volume":"331","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.disamonth.2026.102151_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0014","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1186\/s12889-025-23492-8","article-title":"The global, regional, and national burden of parkinson's disease in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"25","author":"Li","year":"2025","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.disamonth.2026.102151_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120754","article-title":"Neurological disorders and disability in Pakistan: a cross-sectional multicenter study","volume":"452","author":"Wasay","year":"2023","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.70705","article-title":"Current advancement and patient outcomes in reperfusion brain injuries after stroke: a comparative analysis of thrombolysis and thrombectomy","volume":"15","author":"Ayomide","year":"2025","journal-title":"Brain Behav"},{"key":"10.1016\/j.disamonth.2026.102151_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113518","article-title":"Emerging neuroprotective strategies for the treatment of ischemic stroke: an overview of clinical and preclinical studies","volume":"335","author":"Paul","year":"2021","journal-title":"Exp Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0019","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.reth.2021.09.009","article-title":"Current status of ischemic stroke treatment: from thrombolysis to potential regenerative medicine","volume":"18","author":"Hurd","year":"2021","journal-title":"Regen Ther"},{"key":"10.1016\/j.disamonth.2026.102151_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00712","article-title":"From metabolism to mind: the expanding role of the GLP-1 receptor in neurotherapeutics","volume":"22","author":"Roy","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.disamonth.2026.102151_bib0021","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0022","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1134\/S0022093025050023","article-title":"Glucagon-like peptide-1 receptor agonists are promising for the treatment of brain diseases: an outlook from the perspective of integrative physiology","volume":"61","author":"Gulyaeva","year":"2025","journal-title":"J Evol Biochem Physiol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0023","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide 1 (GLP-1) receptor agonists Central nervous system (CNS) penetrant: a narrative review","volume":"14","author":"West","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.disamonth.2026.102151_bib0024","article-title":"Exploring the multifaceted roles of GLP-1 receptor agonists","volume":"6","author":"Hammad","year":"2025","journal-title":"Front Clin Diabetes Heal"},{"key":"10.1016\/j.disamonth.2026.102151_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262412163","article-title":"GLP-1 signalling as a therapeutic avenue in Parkinson's disease: a comprehensive review","volume":"26","author":"Orozco","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0026","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis","volume":"83","author":"Nogueira","year":"2025","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.disamonth.2026.102151_bib0027","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1212\/WNL.0000000000211906","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for Parkinson's Disease: a systematic review and meta-analysis of randomized controlled trials (P11-5.012)","volume":"104","author":"Waseem","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2026.102151_bib0028","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10072-026-08929-1","article-title":"Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials","volume":"47","author":"Ali","year":"2026","journal-title":"Neurol Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0029","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2032s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj"},{"key":"10.1016\/j.disamonth.2026.102151_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2026.104870","article-title":"Molecular evidence associating GLP-1 receptor agonists and brain-derived neurotrophic factors in neurodegenerative and psychiatric disorders: a systematic review","volume":"117","author":"Xu","year":"2026","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.disamonth.2026.102151_bib0031","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194745","article-title":"The promise of GLP-1 receptor agonists for neurodegenerative diseases","volume":"136","author":"Athauda","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.disamonth.2026.102151_bib0032","article-title":"The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0033","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/dom.70400","article-title":"Beyond diabetes and obesity: GLP?1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation","volume":"28","author":"Spezani","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102151_bib0034","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0035","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3233\/JPD-191900","article-title":"The association between type 2 diabetes mellitus and Parkinson's disease","volume":"10","author":"Cheong","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.disamonth.2026.102151_bib0036","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1007\/s12035-023-03359-y","article-title":"Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a mechanistic approach","volume":"60","author":"Sabari","year":"2023","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107132","article-title":"Anti-diabetic drug use and reduced risk of Parkinson's disease: a community-based cohort study","volume":"128","author":"Rozani","year":"2024","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.disamonth.2026.102151_bib0038","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-like peptide-1 receptor agonists and risk of Parkinson's Disease in patients with type 2 Diabetes: a population-based cohort study","volume":"39","author":"Tang","year":"2024","journal-title":"Mov Disord"},{"key":"10.1016\/j.disamonth.2026.102151_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112914","article-title":"Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson's disease in patients with type 2 diabetes: a propensity score-matched cohort study with meta-analysis","volume":"229","author":"Yeh","year":"2025","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.disamonth.2026.102151_bib0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/STROKEAHA.125.053075","article-title":"GLP-1 receptor agonists as treatment of nondiabetic ischemic stroke: a systematic review and meta-analysis","volume":"57","author":"Michaelsen","year":"2026","journal-title":"Stroke"},{"key":"10.1016\/j.disamonth.2026.102151_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13301-y","article-title":"Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"272","author":"Zhang","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0042","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.2147\/DDDT.S559919","article-title":"The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: a review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Devel Ther"},{"key":"10.1016\/j.disamonth.2026.102151_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.disamonth.2026.102151_bib0044","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0045","doi-asserted-by":"crossref","first-page":"21513","DOI":"10.3390\/ijms141121513","article-title":"Neuroprotective effects of liraglutide for stroke model of rats","volume":"14","author":"Sato","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0046","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4103\/bc.bc_38_24","article-title":"Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia\/reperfusion in rats","volume":"10","author":"Mi","year":"2024","journal-title":"Brain Circ"},{"key":"10.1016\/j.disamonth.2026.102151_bib0047","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neuroscience.2014.09.064","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia","volume":"281","author":"Briyal","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.disamonth.2026.102151_bib0048","doi-asserted-by":"crossref","DOI":"10.1007\/s00395-021-00873-9","article-title":"Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke","volume":"116","author":"Nizari","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0049","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/dom.12641","article-title":"Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor","volume":"18","author":"Darsalia","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102151_bib0050","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.4103\/NRR.NRR-D-24-00941","article-title":"Neuroprotective effects of lixisenatide against propagation of ?-synuclein pathology in Parkinson's disease","volume":"21","author":"Sun","year":"2026","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.disamonth.2026.102151_bib0051","article-title":"The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity","volume":"19","author":"Zhang","year":"2025","journal-title":"Front Neurosci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0052","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","article-title":"Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-?B pathway in a mouse model of Parkinson's disease","volume":"37","author":"Cao","year":"2022","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.disamonth.2026.102151_bib0053","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjms.2017.05.002","article-title":"Neuroprotective effects of eexenatide in a rotenone-induced rat model of Parkinson's Disease","volume":"354","author":"Aksoy","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0054","article-title":"DA5-CH and semaglutide protect against neurodegeneration and reduce ?-synuclein levels in the 6-OHDA Parkinson's Disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.disamonth.2026.102151_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.disamonth.2026.102151_bib0056","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces ?-synuclein levels in the chronic MPTP mouse model of Parkinson's Disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.disamonth.2026.102151_bib0057","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.disamonth.2026.102151_bib0058","article-title":"Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0059","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson's disease: a promising direction for therapeutic strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2020.1764534","article-title":"Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease","volume":"29","author":"Glotfelty","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.disamonth.2026.102151_bib0061","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bph.15508","article-title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","volume":"179","author":"H\u00f6lscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0062","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","article-title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease","volume":"26","author":"Yang","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.disamonth.2026.102151_bib0063","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0271678X20952011","article-title":"Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review","volume":"41","author":"Maskery","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.disamonth.2026.102151_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1007980","article-title":"Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102151_bib0065","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1111\/dom.16476","article-title":"Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: a systematic review and meta-analysis","volume":"27","author":"Alammari","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102151_bib0066","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2026.2660386","article-title":"GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers","volume":"58","author":"Chikatimalla","year":"2026","journal-title":"Ann Med"},{"key":"10.1016\/j.disamonth.2026.102151_bib0067","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5853\/jos.2025.00584","article-title":"Glucagon-like peptide-1 receptor agonists in the prevention of ischemic stroke: therapeutic potential and mechanisms","volume":"27","author":"Lin","year":"2025","journal-title":"J Stroke"},{"key":"10.1016\/j.disamonth.2026.102151_bib0068","doi-asserted-by":"crossref","DOI":"10.1177\/11795735261444425","article-title":"GLP-1 receptor agonists in acute ischemic stroke and secondary stroke prevention: a narrative review of preclinical and clinical evidence","volume":"18","author":"Samanidou","year":"2026","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.disamonth.2026.102151_bib0069","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/biomedicines14040743","article-title":"Integrating GLP-1 Receptor agonists into modern stroke prevention: evidence, mechanisms, and clinical consideration-A narrative review","volume":"14","author":"Khan","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.disamonth.2026.102151_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1462240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson's disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2026.102151_bib0071","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251372747","article-title":"GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"18","author":"Tsai","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.disamonth.2026.102151_bib0072","article-title":"The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: a systematic review and meta-analysis","volume":"6","author":"Dahiya","year":"2022","journal-title":"Clin Park Relat Disord"},{"key":"10.1016\/j.disamonth.2026.102151_bib0073","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11892-025-01606-1","article-title":"Targeting metabolic dysfunction in Parkinson's Disease: the role of GLP-1 agonists in body weight regulation and neuroprotection","volume":"25","author":"Aviles-Olmos","year":"2025","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.disamonth.2026.102151_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107220","article-title":"GLP-1 receptor agonists for Parkinson's disease: an updated meta-analysis","volume":"130","author":"Albuquerque","year":"2025","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.disamonth.2026.102151_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1708565","article-title":"GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions","volume":"16","author":"Gandhi","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102151_bib0076","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251408269","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials","volume":"19","author":"Stefanou","year":"2026","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.disamonth.2026.102151_bib0077","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.disamonth.2026.102151_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.disamonth.2026.102151_bib0079","article-title":"Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: real-world evidence from a propensity-matched cohort","volume":"9","author":"AbuAlrob","year":"2025","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.disamonth.2026.102151_bib0080","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1111\/dom.70201","article-title":"Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: a systematic review and meta-analysis based on randomized controlled trials","volume":"28","author":"Wan","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102151_bib0081","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3349\/ymj.2024.0409","article-title":"Adherence to animal research: reporting of In vivo experiments guidelines in stem cell studies in animal models of Parkinson's Disease: a systematic review","volume":"66","author":"Park","year":"2025","journal-title":"Yonsei Med J"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926000891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926000891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:39:27Z","timestamp":1781300367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502926000891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":81,"alternative-id":["S0011502926000891"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102151","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 agonist and neuroprotection in Stroke and Parkinson\u2019s disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102151"}}